Four new biomarkers may enable an earlier stomach cancer diagnosis

Australian researchers say they've zeroed in on four new biomarkers that could enable a simple blood test for the early diagnosis of stomach cancer, far earlier and more precise than existing standards of care. The University of Adelaide team said the proteins--afamin, clusterin, haptoglobin and vitamin D binding protein--each worked better than using the standard CA72-4 as a biomarker to distinguish patients with stomach cancer from healthy controls. They found differences in those four protein levels in blood samples from 37 gastric cancer patients, including 11 with early stage cancer. Details are published in the journal Biochimica et Biophysica Acta. Release | Journal abstract

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.